- Home
- GENK vs CMMB Comparison
GENK vs CMMB Comparison
Compare GENK & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Israel |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 11.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GENK | CMMB |
|---|---|---|
| Price | $2.25 | $1.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.50 | ★ $25.00 |
| AVG Volume (30 Days) | 35.6K | ★ 36.3K |
| Earning Date | 05-13-2026 | 05-21-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | 62.50 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | $43.50 |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $0.87 |
| 52 Week High | $4.98 | $3.86 |
Technical Indicators
Market Signals| Indicator | GENK | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 70.67 | 65.32 |
| Support Level | $2.20 | $1.44 |
| Resistance Level | $2.55 | $2.24 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 69.10 | 86.00 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.